Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus-cmv fusion peptide vaccine
- Development stage
- Phase 1
- Lead developer
- City of Hope Medical Center
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
The tetanus-CMV fusion peptide vaccine is a candidate therapeutic and prophylactic vaccine designed to elicit cytotoxic T-lymphocyte (CTL) responses against cytomegalovirus (CMV), particularly in immunocompromised individuals such as hematopoietic cell transplant recipients. It consists of the HLA A*0201-specific CMV pp65(495-503) cytotoxic CD8+ T-cell epitope fused to a universal T-helper epitope derived from the natural tetanus toxin sequence. This design aims to enhance both helper and cytotoxic T-cell responses for improved protection against CMV infection or reactivation[1][5][3]. Clinical trials have demonstrated its safety and ability to expand pp65(495-503)-specific T cells, especially when coadministered with the adjuvant PF03512676[1][5]. The primary indication is prevention or control of CMV complications in high-risk populations.
- Other names
- tetanus-CMV fusion peptidetetanus-cytomegalovirus fusion peptide vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)MHC II (Major histocompatibility complex class II receptor)TCR (T cell antigen receptor complex)T-cell receptor recognizing pp65/HLA-A*02:01 complexpp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on tetanus-cmv fusion peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus-cmv fusion peptide vaccine.